Abstract
Background and Aim: We sought to compare the efficacy and tolerability of an omeprazole/ clarithromycin/bismuth/tetracycline-based quadruple therapy to that of a ranitidine/metronidazole/ bismuth/tetracycline-based quadruple therapy of 2 or 3 weeks duration in a population with a high prevalence of metronidazole-resistant Helicobacter pylori and low triple therapy eradication rates.
Methods: Two hundred and twenty-one patients who presented endoscopically proven duodenal ulcers and a positive rapid urease test were randomized to receive either: (i) omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d (OCBT) for 2 weeks; (ii) ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT2) for 2 weeks; or (iii) ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT3) for 3 weeks. Patients were interviewed 2 weeks after the completion of therapy to review compliance and side-effects. Eradication of H. pylori was assessed 8 weeks after the completion of therapy with the use of a C-14-urea breath test.
Results: The per-protocol eradication rate was significantly higher with OCBT (88%) than RMBT2 (73%) or RMBT3 (71%) (P < 0.05). The intent-to-treat eradication rate was numerically higher with OCBT (80%) than RMBT2 (68%) or RMBT3 (68%), although this difference did not reach statistical significance (P = 0.09). Per-protocol or intent-to-treat eradication rates were similar with RMBT2 and RMBT3. There were significantly greater side-effects with the RMBT2 regimen.
Conclusions: The omeprazole/clarithromycin/bismuth/tetracycline-based quadruple therapy provides higher H. pylori eradication rates than the ranitidine/metronidazole/bismuth/tetracycline-based quadruple therapy when administered per protocol. The prolongation of the latter regimen from 2 to 3 weeks did not increase eradication rates. (C) 2001 Blackwell Science Asia Pry Ltd.
Original language | English |
---|---|
Pages (from-to) | 264-268 |
Number of pages | 5 |
Journal | Journal of gastroenterology and hepatology |
Volume | 16 |
Issue number | 3 |
DOIs | |
Publication status | Published - Mar-2001 |
Externally published | Yes |
Keywords
- Antibiotic resistance
- Helicobacter pylori
- Treatment
- bismuth citrate
- carbon 14
- clarithromycin
- metronidazole
- omeprazole
- ranitidine
- tetracycline
- urea
- adult
- antibiotic resistance
- article
- breath analysis
- clinical protocol
- clinical trial
- controlled clinical trial
- controlled study
- drug efficacy
- drug tolerability
- duodenum ulcer
- eradication therapy
- female
- gastrointestinal symptom
- Gram negative infection
- human
- major clinical study
- male
- outcomes research
- prevalence
- priority journal
- randomized controlled trial
- xerostomia